Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
- Status
- COMPLETED
- Phase
- PHASE2
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE4
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.
- Status
- UNKNOWN
- Phase
- N/A
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE4
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
GO-203-2C + Bortezomib For Relapsed Or Refractory MM
- Status
- WITHDRAWN
- Phase
- PHASE1
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE4